c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

Brahmachari, Saurav; Karuppagounder, Senthilkumar S; Ge, Preston; Lee, Saebom; Dawson, Valina L; Dawson, Ted M; Ko, Han Seok

Brahmachari, Saurav; Karuppagounder, Senthilkumar S; Ge, Preston; Lee, Saebom; Dawson, Valina L; Dawson, Ted M; Ko, Han Seok.

Afiliação

Brahmachari S; Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Karuppagounder SS; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ge P; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
Lee S; Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dawson VL; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dawson TM; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
Ko HS; Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

J Parkinsons Dis ; 7(4): 589-601, 2017.

Article em En | MEDLINE | ID: mdl-29103051

Assuntos

Doença de Parkinson/metabolismo; Doença de Parkinson/terapia; Proteínas Proto-Oncogênicas c-abl/metabolismo; Envelhecimento; Animais; Humanos; Mesilato de Imatinib/uso terapêutico; Estresse Oxidativo/fisiologia; Inibidores de Proteínas Quinases/uso terapêutico; Proteínas Proto-Oncogênicas c-abl/antagonistas & inibidores; alfa-Sinucleína/metabolismo

Palavras-chave

Alpha-synuclein; Parkinson's disease; biomarkers; c-Abl; c-Abl inhibitors; oxidative stress; parkin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Proteínas Proto-Oncogênicas c-abl Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google